170 related articles for article (PubMed ID: 37057827)
1. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
[TBL] [Abstract][Full Text] [Related]
2. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
[TBL] [Abstract][Full Text] [Related]
3. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies.
Long MD; Schreiber S; Hibi T; Gibble TH; Fisher DA; Park G; Moses RE; Higgins PDR; Lindsay JO; Lee SD; Escobar R; Jairath V
Crohns Colitis 360; 2024 Jan; 6(1):otae001. PubMed ID: 38313767
[TBL] [Abstract][Full Text] [Related]
4. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE; D'Haens G; Clemow DB; Irving PM; Johns JT; Hunter Gibble T; Abreu MT; Lee S; Hisamatsu T; Kobayashi T; Dubinsky MC; Vermeire S; Siegel CA; Peyrin-Biroulet L; Moses RE; Milata J; Arora V; Panaccione R; Dignass A
Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38459910
[TBL] [Abstract][Full Text] [Related]
5. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38869019
[TBL] [Abstract][Full Text] [Related]
6. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
[TBL] [Abstract][Full Text] [Related]
7. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
[TBL] [Abstract][Full Text] [Related]
8. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
Parkes G; Ungaro RC; Danese S; Abreu MT; Arenson E; Zhou W; Ilo D; Laroux FS; Deng H; Sanchez Gonzalez Y; Peyrin-Biroulet L
J Gastroenterol; 2023 Oct; 58(10):990-1002. PubMed ID: 37490069
[TBL] [Abstract][Full Text] [Related]
9. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Gibble TH; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T
Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38271613
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Kobayashi T; Matsuoka K; Watanabe M; Hisamatsu T; Hirai F; Milata J; Li X; Morris N; Arora V; Ishizuka T; Matsuo K; Satoi Y; Milch C; Hibi T
Intest Res; 2024 Apr; 22(2):172-185. PubMed ID: 38720466
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
[TBL] [Abstract][Full Text] [Related]
13. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
[TBL] [Abstract][Full Text] [Related]
14. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
Chua L; Friedrich S; Zhang XC
Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
[TBL] [Abstract][Full Text] [Related]
15. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
Hanzel J; Ma C; Jairath V
Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
[TBL] [Abstract][Full Text] [Related]
16. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
17. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
Bryant RV; Burger DC; Delo J; Walsh AJ; Thomas S; von Herbay A; Buchel OC; White L; Brain O; Keshav S; Warren BF; Travis SP
Gut; 2016 Mar; 65(3):408-14. PubMed ID: 25986946
[TBL] [Abstract][Full Text] [Related]
18. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
[TBL] [Abstract][Full Text] [Related]
19. Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes.
Chen R; Tie Y; Huang Y; Zhang X; Zeng Z; Chen M; Li L; Zhang S
United European Gastroenterol J; 2024 May; 12(4):459-468. PubMed ID: 38159047
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study.
Verstockt B; Pouillon L; Ballaux F; Jorissen C; Hoefkens E; Lembrechts N; Bossuyt P
J Crohns Colitis; 2023 Jul; 17(7):1046-1054. PubMed ID: 36708189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
